CAR-T trial for kids with rare vasculitis withdrawn before starting
NCT ID NCT06508346
First seen Jun 20, 2026 · Last updated Jun 20, 2026
Summary
This study planned to test anti-CD19 CAR-T cells in children aged 5-25 with refractory ANCA-associated vasculitis, a rare autoimmune disease. The trial was withdrawn before enrolling any participants, so no results or conclusions are available. CAR-T therapy aims to reset the immune system by targeting certain immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19 CAR-T cells
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.